Most Cost-Effective Screening for Bleeding Disorders in Heavy Menstrual Bleeding
For a 50-year-old woman with heavy menstruation, use a validated bleeding assessment tool (BAT) as the initial screening test, followed by specific laboratory testing only if the BAT score is abnormal (≥6 for women over 30 years). This approach is the most cost-effective strategy that balances diagnostic accuracy with resource utilization 1.
Algorithmic Approach to Screening
Step 1: Initial Clinical Screening with BAT
- Start with a validated bleeding assessment tool (self-BAT, ISTH-BAT, or Philipp tool) as your first-line screening 1, 2
- For women aged 31-52 years, an abnormal score is ≥6 3
- The 2025 VWD diagnostic guidelines specifically recommend BATs as initial screening tools in primary care settings to determine who requires laboratory testing 1
- This is the most cost-effective approach because it triages patients before expensive laboratory workup
Step 2: Assess Clinical Red Flags
Before ordering labs, document:
- Family history of bleeding disorders (present in ~11% of women with bleeding symptoms) 4
- Medication use: Aspirin or NSAIDs (affects 88% of assessments) 5
- Hypermobility assessment using Beighton score (associated with bleeding symptoms) 5
- Iron deficiency: Check CBC and ferritin (often overlooked despite high prevalence in bleeding disorders) 5
Step 3: Laboratory Testing (Only if BAT Abnormal)
If BAT score is abnormal, order this initial panel:
- Complete blood count and ferritin (65-69% of clinicians use first-line) 5
- VWF antigen and VWF activity assays (newer GPIb-based assays preferred over VWF:RCo) 1
- Factor VIII level
- aPTT, PT, and fibrinogen (Clauss method) 5
Critical caveat: Standard screening tests (aPTT, PT, PFA-100/200) can be completely normal in mild bleeding disorders, including von Willebrand disease 1. If clinical suspicion remains high despite normal screening, proceed directly to specific factor assays.
Why This Approach is Most Cost-Effective
Evidence for BAT-First Strategy
The 2025 ASH-ISTH-NHF-WFH guidelines explicitly recommend using BATs as initial screening in primary care settings to determine who needs laboratory testing 1. This prevents unnecessary testing in women without true bleeding disorders.
Cost Considerations
- BATs are free or minimal cost (self-administered questionnaires)
- Laboratory panels cost significantly more: A full hemostatic workup can be expensive and resource-intensive 5
- Studies show that 10-62% of women with HMB have underlying bleeding disorders 2, but universal laboratory screening would be wasteful
- Selective testing based on BAT scores reduces costs by ~30% without compromising diagnostic accuracy 6
Limitations of Alternative Screening Tests
- PFA-100/200: Only 37% sensitivity for mild VWD; useful for severe cases but misses mild disorders 1, 5
- Bleeding time: Discontinued due to poor reproducibility and invasiveness 1
- aPTT/PT alone: Can be completely normal in VWD and mild factor deficiencies 1
Common Pitfalls to Avoid
Don't skip the BAT: Jumping directly to laboratory testing without structured bleeding history assessment leads to over-testing and missed diagnoses 1, 5
Don't rely on PFA-100/200 alone: While 37% of clinicians use it first-line 5, it has poor sensitivity for mild bleeding disorders 1, 5
Don't forget iron studies: Despite high prevalence of iron deficiency in bleeding disorders, 27-31% of clinicians don't check CBC/ferritin 5
Don't assume normal screening tests exclude bleeding disorders: Up to 60-70% of patients with true bleeding phenotypes have normal standard laboratory tests (BDUC) 5
When to Refer to Hematology
Refer if:
- Abnormal BAT score with abnormal laboratory findings
- Strong family history of bleeding disorders
- Abnormal BAT with normal initial labs but persistent clinical concern
- Recurrent or severe bleeding episodes requiring transfusion
The BAT-first approach maximizes cost-effectiveness by preventing unnecessary laboratory testing in women without bleeding disorders while ensuring appropriate workup for those at risk 1, 2, 3.